Jazz completes $820M upfront acquisition of Actio Biosciences for KCNT1 epilepsy drug ABS-1230

Jazz Pharmaceuticals plc

Jazz completed $820M upfront acquisition of Actio Biosciences; Actio now a wholly-owned subsidiary.
ABS-1230 is a first-in-class oral KCNT1 inhibitor; inhibited all evaluable mutations in preclinical studies.
In early clinical proof-of-concept, children with KCNT1-related epilepsy had meaningful seizure reductions.
FDA granted Fast Track, Rare Pediatric Disease and Orphan Drug designations for ABS-1230.
Actio spun off non-ABS-1230 programs into a new company; Jazz received a minority stake.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.